Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response study of Phleum pratense allergoid in adults with allergic rhinitis/rhinoconjunctivitis
2011-000674-58Phase 2Completed
- Sponsor
- Allergopharma
- Start
- Apr 2011
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and allergic asthma comparing Allergovit dose arm(s) with Placebo (2 arms). Primary endpoint: Change in late phase skin reaction swelling area. Started Apr 2011; status: completed.
02
Drugs
Allergovit
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2011-000674-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000674-58.